MCM
AMPH icon

MAI Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

MAI Capital Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.27K Buy
371
+13
+4% +$318 ﹤0.01% 3319
2025
Q4 		$9.59K Buy
358
+300
+517% +$7.73K ﹤0.01% 2871
2025
Q3 		$1.55K Sell
58
-128
-69% -$3.31K ﹤0.01% 3373
2025
Q2 		$4.27K Buy
+186
New +$4.62K ﹤0.01% 3127

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

MAI Capital Management's AMPH Position: Q1 2026 in Review

MAI Capital Management increased its Amphastar Pharmaceuticals (AMPH) stake by 3.6% in Q1 2026, buying an estimated $318 and bringing the position to 371 shares worth $7.27K. The position accounts for ﹤0.01% of the portfolio, ranked #3319.

MAI Capital Management first reported a position in AMPH in Q2 2025 and has held it in 4 quarters since. The position peaked at $9.59K in Q4 2025. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

  • MAI Capital Management held 371 shares of Amphastar Pharmaceuticals worth $7.27K as of Q1 2026.
  • MAI Capital Management bought 13 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $318.
  • Amphastar Pharmaceuticals made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #3319 holding.
  • MAI Capital Management first reported a position in Amphastar Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • MAI Capital Management's Amphastar Pharmaceuticals position peaked at $9.59K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.